Non-invasive energy upconversion methods and systems for in-situ photobiomodulation

Patent metadata

Field	Value
Publication number	US-9302116-B2
Application number	US-76418410-A
Country	US
Kind code	B2
Filing date	Apr 21, 2010
Priority date	Nov 6, 2007
Publication date	Apr 5, 2016
Grant date	Apr 5, 2016

Abstract

Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ 1 , to generate a second wavelength λ 2 of radiation having a higher energy than the first wavelength λ 1 . The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

First claim

The invention claimed is:

1. A method for treating a cell proliferation disease, comprising:
placing a nanoparticle in a vicinity of a target structure in a subject in need of treatment, wherein the nanoparticle is configured, upon exposure to a first wavelength λ 1 , to generate a second wavelength λ 2 of radiation having a higher energy than the first wavelength λ 1 ,
applying an initiation energy which includes said first wavelength λ1 from an initiation energy source to the subject having the placed nanoparticle, wherein the nanoparticle emits light in the vicinity of or into the target structure upon interaction with the initiation energy, wherein the emitted light includes said second wavelength λ2 which directly contacts a target structure and treats the cell proliferation disease in situ.

2. The method of claim 1 , wherein:
the nanoparticle comprises a metallic structure deposited in relation to the nanoparticle, and
a physical characteristic of the metallic structure is set to a value so that a surface plasmon resonance in the metallic structure resonates at a frequency which provides spectral overlap with at least one the first wavelength λ1 and the second wavelength λ2.

3. The method of claim 2 , wherein the nanoparticle comprises a dielectric core.

4. The method of claim 2 , wherein the metallic structure comprises at least one element selected from the group consisting of Au, Ag, Cu, Ni, Pt, Pd, Co, Ru, Rh, Al, Ga, and alloys or layers thereof.

5. The method of claim 2 , wherein the metallic structure comprises at least one structure selected from the group consisting of a conducting material including at least one metal, a doped glass, and a doped semiconductor.

6. The method of claim 5 , wherein the conducting material comprises at least one elemental metal, an alloy of the element metal, or layers of the conducting materials.

7. The method of claim 2 , wherein:
the nanoparticle comprises a sub 1000 nm dielectric particle;
the dielectric particle comprises at least one compound selected from the group consisting of Y 2 O 3 , Y 2 O 2 S, NaYF 4 , NaYbF 4 , YAG, YAP, Nd 2 O 3 , LaF 3 , LaCl 3 , La 2 O 3 , TiO 2 , LuPO 4 , YVO 4 , YbF 3 , YF 3 , Na-doped YbF 3 , SiO 2 and alloys or layers thereof;
the dielectric particle comprises a dopant comprising Er, Eu, Yb, Tm, Nd, Tb, Ce, Y, U, Pr, La, Gd or other rare-earth species or a combination thereof;
the dopant has a concentration of 0.01%-50% by mole; and
the metallic structure includes at least one element selected from the group consisting of Au, Ag, Cu, Ni, Pt, Pd, Co, Ru, Rh, Al, Ga, and alloys or layers thereof.

8. The method of claim 1 , wherein the nanoparticle comprises a dielectric core.

9. The method of claim 8 , wherein the dielectric core has a diameter ranging from 2 nm to 100 nm.

10. The method of claim 1 , wherein the nanoparticle comprises at least one compound selected from the group consisting of Y 2 O 3 , Y 2 O 2 S, NaYF 4 , NaYbF 4 , YAG, YAP, Nd 2 O 3 , LaF 3 , LaCl 3 , La 2 O 3 , TiO 2 , LuPO 4 , YVO 4 , YbF 3 , YF 3 , Na-doped YbF 3 , SiO 2 , and alloys or layers thereof.

11. The method of claim 1 , wherein the nanoparticle comprises a dopant including at least one element selected from the group consisting of Er, Eu, Yb, Tm, Nd, Tb, Ce, Y, U, Pr, La, Gd, other rare-earth species and a combination thereof.

12. The method of claim 11 , wherein the dopant is present in an amount of from 0.01% to 50 mol. %.

13. The method of claim 1 , wherein the initiation energy is capable of penetrating completely through said subject.

14. The method of claim 1 , wherein applying comprises:
applying the initiation energy from (i) an initiation energy source that is external to the subject; or (ii) an initiation energy source that is internal to the subject, which is placed or delivered internally into the subject and/or the target structure.

15. The method of claim 1 , wherein applying comprises applying said initiation energy from a source emitting at least one energy selected from the group consisting of visible light, infrared radiation, microwaves, and radio waves.

16. The method of claim 1 , wherein said initiation energy is energy emitted by at least one cell excited by one or more metabolic processes and said applying is conducted via a cell-to-cell energy transfer.

17. The method of claim 1 , wherein said initiation energy is energy emitted by at least one cell and said applying is conducted via cell-to-cell energy transfer.

18. The method of claim 1 , in which an activity of the target structure is enhanced.

19. The method of claim 18 , wherein the activity enhanced is energy emission from the target, which then mediates, initiates or enhances a biological activity of other target structures in the subject, or of a second target structure.

20. The method of claim 1 , wherein the nanoparticle comprises a dielectric, a glass, a semiconductor, or a combination thereof.

21. The method of claim 1 , wherein:
the nanoparticle comprises a sub 1000 nm dielectric particle; and
the dielectric particle comprises at least one compound selected from the group consisting of Y 2 O 3 , Y 2 O 2 S, NaYF 4 , NaYbF 4 , YAG, YAP, Nd 2 O 3 , LaF 3 , LaCl 3 , La 2 O 3 , TiO 2 , LuPO 4 , YVO 4 , YbF 3 , YF 3 , Na-doped YbF 3 , SiO 2 and alloys or layers thereof.

22. The method of claim 21 , wherein the dielectric particle has a diameter ranging from at least one of 2-1000 nm, 2-100 nm, 2-50 nm, 2-20 nm, or 2-10 nm.

23. The method of claim 1 , wherein said nanoparticle has an upconversion capability to produce, from first said wavelength λ 1 of radiation, an upconverted light of said second wavelength λ 2 , and the method further comprising administering an X-ray down-converter particle having a down conversion capability to produce down converted light and application of X-rays to the subject.

24. The method of claim 1 , in which the predetermined change results in destruction, lysis or inactivation of the target structure.

25. The method of claim 1 , wherein the target structure is a eukaryotic cell.

26. The method of claim 1 , wherein the target structure is a prokaryotic cell.

27. The method of claim 1 , wherein the target structure is a subcellular structure.

28. The method of claim 27 , wherein the subcellular structure is a cell membrane, a nuclear membrane, cell nucleus, nucleic acid, mitochondria, ribosome, or other cellular organelle or component.

29. The method of claim 1 , wherein the target structure is an extracellular structure.

30. The method of claim 1 , wherein the target structure is a virus or prion.

31. The method of claim 1 , wherein said cell proliferation disease is cancer.

32. The method of claim 1 , wherein said disease is an enlarged prostate, colon cancer, breast cancer, or lung cancer.

33. The method of claim 1 , wherein said disease is mediated by abnormal cellular proliferation and said treatment ameliorates the abnormal cellular proliferation.

34. The method of claim 33 , wherein said abnormal cellular proliferation is higher than that of cells from a subject not having said disease.

35. The method of claim 33 , wherein said abnormal cellular proliferation is lower than that of cells from a subject not having said conditio

Assignees

• Vo-Dinh Tuan
• Scaffidi Jonathan P
• Chada Venkata Gopal Reddy
• Lauly Benoit
• Zhang Yan
• Gregas Molly K
• Stanton Ian N
• Stecher Joshua T
• Therien Michael J
• Bourke Jr Frederic A
• Walder Harold
• Fathi Zak
• Ayres Jennifer A
• Zhang Zhenyuan
• Simmons Joseph H
• Norton Stephen John
• Univ Duke
• Immunolight Llc

Inventors

• Vo-Dinh Tuan
• Scaffidi Jonathan P
• Chada Venkata Gopal Reddy
• Lauly Benoit
• Zhang Yan
• Gregas Molly K
• Stanton Ian N
• Stecher Joshua T
• Therien Michael J
• Bourke Jr Frederic A
• Walder Harold
• Fathi Zak
• Ayres Jennifer A
• Zhang Zhenyuan
• Simmons Joseph H
• Norton Stephen John

Classifications

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P9/06

  Antiarrhythmics · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title